ARGX - ア―ジェンクスSE （argenx SE） ア―ジェンクスSEARGXのチャート
ARGXの企業情報
| symbol | ARGx |
|---|---|
| 会社名 | argenx SE （ア―ジェンクスSE） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アルジェン(argenx SE)(旧名: arGEN X BV)はオランダに本拠を置くバイオ医薬品会社である。同社はラマ免疫系の特徴を利用する発見プラットフォームであるSimple Antibodyを用いて、分化した抗体治療薬のパイプラインを製造・開発する。同社はがん及び自己免疫適応に重点を置いた抗体治療薬のパイプラインを開発する。そのパイプラインは細胞増殖・生存などの腫瘍の機能を調節するヘム悪性腫瘍及び固形腫瘍のための抗体であるARGX-110、複数の固形腫瘍における細胞増殖、血管新生及び転移に関与する受容体チロシンキナーゼであるc-MetのアンタゴニストのARGX-111、並びにそれらの共通の受容体の遮断によるシグナル伝達を媒介されるIL-20及びIL-22（インターロイキン）の中和により、アトピー性皮膚炎を標的とする抗原であるARGX-112を含む。 ア―ジェンクスSEはオランダのバイオ医薬品企業。臨床ステ―ジで、主にがんと自己免疫病の治療薬の開発・商品化に従事する。新規の発見・開発に取り組むと同時に、既知の治療法に対する研究も進める。同社臨床パイプラインは抗体エンジニアリングと同社「Simple Antibody」プラットフォ―ムはラマ免疫系の治療法などを含む。本社所在地はブレダ。 |
| 本社所在地 | Willemstraat 5 Breda 4811 AH NLD |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 39539 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | 73人 |
| url | www.argenx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/argx |
| adr_tso | 18157259 |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 70.795 |
| 時価総額（marketcap） | 1285443150.905 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
ARGXのテクニカル分析
ARGXのニュース
Bvf Inc Buys GH Research PLC, argenx SE, Syndax Pharmaceuticals Inc, Sells , Ionis ... 2021/08/24 21:38:35 GuruFocus
Related Stocks: ARGX , SNDX , RCUS , FDMT , RACA , REPL , GHRS , VIRX , RAIN , JANX , IKNA , DAWN , FPRX , IONS , IDYA , CTMX ,
Argenx Se (ARGX): Price Now Near $300.35; Daily Chart Shows An Uptrend on 20 Day Basis 2021/07/01 15:14:52 ETF Daily News
It''s been a feast for bears operating on the daily timeframe, as argx has now gone down 4 of the past 5 days. The post Argenx Se (ARGX): Price Now Near $300.35; Daily Chart Shows An Uptrend on 20 Day Basis appeared first on ETF Daily News .
Argenxs drug effective against muscle-weakening disease myasthenia gravis 2021/06/16 22:30:41 Financial Post
An experimental drug developed by argenx SE led to improvements in daily activities, including chewing and swallowing, in patients suffering from a muscle-weakening autoimmune disease, according to data published in the Lancet Neurology medical journal on Wednesday. The late-stage study met its main goal of demonstrating that a greater percentage of patients on the treatment []
Argenx Se (ARGX): Price Now Near $300.35; Daily Chart Shows An Uptrend on 20 Day Basis 2021/07/01 15:14:52 ETF Daily News
It''s been a feast for bears operating on the daily timeframe, as argx has now gone down 4 of the past 5 days. The post Argenx Se (ARGX): Price Now Near $300.35; Daily Chart Shows An Uptrend on 20 Day Basis appeared first on ETF Daily News .
Argenxs drug effective against muscle-weakening disease myasthenia gravis 2021/06/16 22:30:41 Financial Post
An experimental drug developed by argenx SE led to improvements in daily activities, including chewing and swallowing, in patients suffering from a muscle-weakening autoimmune disease, according to data published in the Lancet Neurology medical journal on Wednesday. The late-stage study met its main goal of demonstrating that a greater percentage of patients on the treatment []
Robert W. Baird Stick to Their Buy Rating for Argenx Se By Investing.com 2021/06/10 04:48:01 Investing.com
Robert W. Baird Stick to Their Buy Rating for Argenx Se
Argenx Se (ARGX) was Downgraded to a Hold Rating at Kepler Capital 2021/06/09 02:06:08 Smarter Analyst
Argenx Se (ARGX) received a Hold rating and a EUR220.00 price target from Kepler Capital analyst Damien Choplain on June 7. The post Argenx Se (ARGX) was Downgraded to a Hold Rating at Kepler Capital appeared first on Smarter Analyst .
Wedbush Stick to Their Buy Rating for Argenx Se By Investing.com 2021/06/09 01:45:23 Investing.com
Wedbush Stick to Their Buy Rating for Argenx Se
Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab 2021/06/07 12:31:41 Benzinga
Johnson & Johnson (NYSE: JNJ ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX ) for the CD70-targeting cusatuzumab. The pair first came together to develop the med across various blood cancers and disorders in December 2018 . J&J said in a brief statement, "The decision is based upon Janssen's review of all available cusatuzumab data and in consideration of the evolving standard of care for the … Full story available on Benzinga.com
Argenx To Regain Global Rights To Anti-CD70 Antibody Cusatuzumab From Janssen's Cilag 2021/06/07 05:43:19 Business Insider Markets
(RTTNews) - argenx SE (ARGX), an immunology company, announced Monday that it will regain worldwide rights to its anti-CD70 antibody cusatuzumab from Cilag GmbH International, part of Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ). The company noted that interim data from the Phase 1b ELEVATE trial support continued development in…